Archives

Ozempic (semaglutide), a GLP-1 receptor agonist developed by Novo Nordisk, is a cornerstone treatment for type 2 diabetes and is increasingly prescribed for weight management. Yet, navigating [...]

Zepbound (tirzepatide), a GLP-1 receptor agonist developed by Eli Lilly, has emerged as a promising treatment for chronic weight management. However, obtaining insurance approval through prior [...]

Transitioning to a new Electronic Health Record (EHR) system is one of the most disruptive and necessary events a medical practice can experience. It doesn’t matter if you are transitioning [...]

Wegovy (semaglutide), developed by Novo Nordisk, has become a vital medication in managing obesity. Yet, securing prior authorization (PA) approval from insurers remains a critical barrier. This [...]

🎉 Happy National Nurses Week! 🎉 At DataMatrix Medical, we’re proud to support the frontline heroes who keep our healthcare system running—especially nurses. This week, from May 6 to 12, we [...]